Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SLQT
SLQT logo

SLQT Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.200
Open
1.160
VWAP
1.17
Vol
1.10M
Mkt Cap
204.56M
Low
1.140
Amount
1.28M
EV/EBITDA(TTM)
10.86
Total Shares
176.35M
EV
823.89M
EV/OCF(TTM)
--
P/S(TTM)
0.13
SelectQuote, Inc. provides a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. The Company has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote Healthcare Services comprises SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with healthcare services that fit each member's healthcare needs. SelectQuote’s Auto & Home division primarily sells non-commercial auto and home, property and casualty insurance products. SelectQuote’s Life division sells term life, final expenses, and other ancillary products. SelectRx is a Patient-Centered Pharmacy Home (PCPH) accredited pharmacy.
Show More

Events Timeline

(ET)
2026-05-05
07:30:00
SelectQuote Reports Q3 Revenue of $430.9M
select
2026-03-25 (ET)
2026-03-25
16:20:00
SelectQuote Faces NYSE Compliance Issue as Stock Price Falls Below $1
select
2026-01-15 (ET)
2026-01-15
07:10:00
SelectQuote Reaches New Agreement with Long-Time PBM Partner
select
2025-08-21 (ET)
2025-08-21
07:37:32
SelectQuote Announces Q4 EPS of 2 Cents, Below Consensus Estimate of 13 Cents
select
2025-07-02 (ET)
2025-07-02
16:16:03
SelectQuote vice chairman Tom Grant passes away
select
2025-05-12 (ET)
2025-05-12
07:36:04
SelectQuote sees FY25 revenue $1.5B-$1.575B, consensus $1.53B
select

News

seekingalpha
9.5
05-05seekingalpha
SelectQuote Reports Strong Q3 2026 Earnings with Positive Outlook
  • Strong Financial Performance: SelectQuote generated $431 million in revenue for Q3 2026, reflecting a 6% year-over-year increase, with adjusted EBITDA reaching $45 million, indicating robust growth across all business segments and boosting market confidence.
  • Senior Business Growth: Revenue from the Senior segment grew 8% year-over-year to $183 million, demonstrating the company's successful optimization of commission receivables amid improved approval rates for Medicare Advantage policies, with an anticipated asset benefit of approximately $1 billion in the future.
  • SelectRx Challenges and Opportunities: Despite facing headwinds from carrier-specific reimbursement policies and the Inflation Reduction Act, SelectRx's adjusted EBITDA improved sequentially to $5 million, showcasing the company's resilience in seeking profitability in challenging conditions.
  • Optimistic Future Outlook: The company reaffirmed its revenue guidance for fiscal 2026 in the range of $1.61 billion to $1.71 billion and adjusted EBITDA guidance between $90 million and $100 million, with management expressing increased confidence in accelerating cash flow, which is expected to drive growth in fiscal 2027.
seekingalpha
9.5
05-05seekingalpha
SelectQuote Q3 Earnings Beat Expectations Despite Revenue Miss
  • Earnings Beat: SelectQuote reported a Q3 GAAP EPS of $0.11, exceeding expectations by $0.10, indicating stable profitability that could enhance investor confidence in the company's financial performance.
  • Revenue Miss: Despite a year-over-year revenue increase of 5.6% to $430.9 million, the figure fell short of expectations by $8.03 million, highlighting challenges from increased market competition and rising customer acquisition costs that may impact future growth potential.
  • Net Income and Adjusted EBITDA: The company achieved a net income of $40.2 million and an adjusted EBITDA of $44.6 million, demonstrating some success in cost control and operational efficiency, which strengthens its overall financial health.
  • Fiscal Year 2026 Guidance: SelectQuote projects revenue for FY 2026 to range between $1.61 billion and $1.71 billion, with adjusted EBITDA expected between $90 million and $100 million, reflecting a cautiously optimistic outlook for future growth despite external challenges.
seekingalpha
9.5
05-04seekingalpha
SelectQuote Scheduled to Announce Q3 Earnings on May 5
  • Earnings Announcement: SelectQuote (SLQT) is set to release its Q3 earnings results on May 5 before market open, with consensus EPS estimated at $0.01 and revenue projected at $438.93 million, reflecting a 33.5% year-over-year growth.
  • Performance Expectations: Over the past year, SelectQuote has exceeded EPS estimates 75% of the time and has beaten revenue estimates 100% of the time, indicating a strong track record of financial performance.
  • Revision Trends: In the last three months, there have been no upward revisions to EPS estimates and one downward revision, while revenue estimates have seen four downward adjustments, suggesting market caution regarding the company's future outlook.
  • Market Challenges: SelectQuote recently received a notice from the NYSE for having a share price below $1 and has lowered its 2026 guidance amid a $40 million headwind, yet it aims for a senior EBITDA margin of over 20% and operating cash flow between $25 million and $35 million.
Newsfilter
9.5
04-21Newsfilter
SelectQuote to Release Q3 2026 Financial Results on May 5
  • Earnings Release Schedule: SelectQuote will announce its fiscal Q3 2026 financial results before market open on May 5, 2026, which is expected to significantly impact investor sentiment.
  • Executive Conference Call: CEO Tim Danker and CFO Ryan Clement will host a conference call at 8:30 AM ET on the release day to discuss the financial results, enhancing transparency and investor confidence.
  • Company Background: Founded in 1985, SelectQuote pioneered the model of providing unbiased comparisons from multiple highly-rated insurance companies, allowing consumers to choose policies that best meet their needs, showcasing its leadership in the insurance sector.
  • Business Ecosystem: The company operates three core business lines, including SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life, aimed at addressing the growing Medicare needs of approximately 10,000 seniors turning 65 daily, supporting the healthcare insurance demands of 65 million elderly consumers.
Globenewswire
7.0
04-09Globenewswire
SelectQuote Executives Allegedly Breached Fiduciary Duties
  • Legal Investigation Initiated: Kuehn Law, PLLC is investigating whether executives at SelectQuote, Inc. breached their fiduciary duties to shareholders, with allegations that could lead to significant legal repercussions for the company.
  • False Statements Exposed: According to a federal securities lawsuit, SelectQuote is accused of failing to disclose that its recommendations to Medicare beneficiaries were primarily based on compensation to the company rather than the quality or suitability of the insurance plans.
  • Improper Conduct Allegations: SelectQuote is alleged to have failed to provide unbiased comparisons of Medicare Advantage plans and received illegal kickbacks to steer beneficiaries to specific insurers, potentially violating the False Claims Act.
  • Increased Compliance Risks: As a result of these actions, SelectQuote may face regulatory and legal sanctions, leading to previous positive statements about the company being deemed misleading and lacking a reasonable basis.
Newsfilter
7.0
04-09Newsfilter
SelectQuote Executives Allegedly Breached Fiduciary Duties
  • Legal Investigation Launched: Kuehn Law, PLLC is investigating whether executives at SelectQuote, Inc. breached their fiduciary duties to shareholders, with allegations that the company misled investors by failing to disclose its practices regarding Medicare beneficiaries, potentially harming shareholder interests.
  • Misconduct Allegations: The lawsuit claims that SelectQuote directed Medicare beneficiaries to insurers that compensated the company best, rather than providing unbiased comparisons, exposing the firm to legal and regulatory sanctions.
  • Potential Legal Consequences: SelectQuote's actions may have violated the False Claims Act, leading to risks of regulatory and legal penalties that could adversely affect the company's future operations and reputation.
  • Shareholder Rights Protection: Kuehn Law urges shareholders to contact attorneys promptly to protect their rights, emphasizing that shareholder voices are crucial for the integrity and fairness of financial markets.
Wall Street analysts forecast SLQT stock price to rise
3 Analyst Rating
Wall Street analysts forecast SLQT stock price to rise
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
5.00
Averages
6.00
High
7.00
Current: 0.000
sliders
Low
5.00
Averages
6.00
High
7.00
Noble Capital
Outperform
downgrade
$7 -> $5
AI Analysis
2026-02-06
Reason
Noble Capital
Price Target
$7 -> $5
AI Analysis
2026-02-06
downgrade
Outperform
Reason
Noble Capital lowered the firm's price target on SelectQuote to $5 from $7 and keeps an Outperform rating on the shares to reflect updated forecasts and heightened near-term uncertainty following the company's fiscal Q2 report.
Craig-Hallum
Buy
downgrade
$4 -> $3
2026-02-06
Reason
Craig-Hallum
Price Target
$4 -> $3
2026-02-06
downgrade
Buy
Reason
Craig-Hallum lowered the firm's price target on SelectQuote to $3 from $4 and keeps a Buy rating on the shares. The firm notes the company reported Q2 results that were modestly ahead of estimates but lowered the full year guide.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SLQT
Unlock Now

Valuation Metrics

The current forward P/E ratio for SelectQuote Inc (SLQT.N) is 66.67, compared to its 5-year average forward P/E of -3.75. For a more detailed relative valuation and DCF analysis to assess SelectQuote Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.75
Current PE
66.67
Overvalued PE
37.71
Undervalued PE
-45.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.85
Current EV/EBITDA
3.54
Overvalued EV/EBITDA
53.22
Undervalued EV/EBITDA
-51.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.54
Current PS
0.12
Overvalued PS
1.30
Undervalued PS
-0.22

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what stocks should I swing trade
Intellectia · 464 candidates
Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceCrossAboveMA20Week Price Change Pct: >= $0.00Month Price Change Pct: >= $0.00Support Resistance Relationship: PriceBreakResistance, PriceAroundResistanceMonthly Average Dollar Volume: >= 500,000Macd: positive, bullish
Ticker
Name
Market Cap$
top bottom
CREG logo
CREG
Smart Powerr Corp
23.42M
ELPW logo
ELPW
eLong Power Holding Ltd
5.43M
VNCE logo
VNCE
Vince Holding Corp
59.35M
SGML logo
SGML
Sigma Lithium Corp
2.43B
SNBR logo
SNBR
Sleep Number Corp
69.81M
HPP logo
HPP
Hudson Pacific Properties Inc
489.81M
Penny stocks that I should buy today
Intellectia · 20 candidates
Market Cap: 20.00M - 500.00MPrice: $0.05 - $1.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
CUE logo
CUE
Cue Biopharma Inc
49.02M
BURU logo
BURU
NUBURU Inc
29.84M
GAME logo
GAME
GameSquare Holdings Inc
35.43M
GOSS logo
GOSS
Gossamer Bio Inc
96.11M
CAN logo
CAN
Canaan Inc
303.68M
GPRO logo
GPRO
GoPro Inc
126.03M
lowest share costing stocks
Intellectia · 53 candidates
Market Cap: >= 50.00MRegion: USPrice: <= $1.00List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
KALA logo
KALA
KALA BIO Inc
195.30M
MREO logo
MREO
Mereo BioPharma Group PLC
55.83M
SGMO logo
SGMO
Sangamo Therapeutics Inc
130.65M
OPTT logo
OPTT
Ocean Power Technologies Inc
86.12M
IMMP logo
IMMP
Immutep Ltd
54.23M
GOSS logo
GOSS
Gossamer Bio Inc
89.54M
what should I buy under 1.00 a share?
Intellectia · 344 candidates
Price: $0.10 - $1.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
ALIT logo
ALIT
Alight Inc
507.72M
UP logo
UP
Wheels Up Experience Inc
406.86M
LAB logo
LAB
Standard BioTools Inc
392.26M
GETY logo
GETY
Getty Images Holdings Inc
360.43M
BYND logo
BYND
Beyond Meat Inc
352.61M
CAN logo
CAN
Canaan Inc
345.29M
pennystocks
Intellectia · 37 candidates
Market Cap: <= 300.00MPrice: <= $5.00Beta: HighRiskWeekly Average Turnover: >= 1,000,000Month Price Change Pct: >= $10.00
Ticker
Name
Market Cap$
top bottom
ASPN logo
ASPN
Aspen Aerogels Inc
295.88M
SLQT logo
SLQT
SelectQuote Inc
283.31M
STTK logo
STTK
Shattuck Labs Inc
280.96M
AVIR logo
AVIR
Atea Pharmaceuticals Inc
275.01M
JELD logo
JELD
JELD-WEN Holding Inc
258.00M
TYGO logo
TYGO
Tigo Energy Inc
243.42M
good penny stocks to invest in
Intellectia · 32 candidates
Market Cap: <= 500.00MPrice: <= $5.00Quarter Revenue Yoy Growth: >= 10.0%Beta: HighRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
CAN logo
CAN
Canaan Inc
498.64M
ORGO logo
ORGO
Organogenesis Holdings Inc
487.34M
CERS logo
CERS
Cerus Corp
485.98M
OCGN logo
OCGN
Ocugen Inc
465.36M
API logo
API
Agora Inc
402.42M
NNDM logo
NNDM
Nano Dimension Ltd
395.43M
Best stock under 3.50 that will 3x
Intellectia · 29 candidates
Market Cap: <= 2.00BPrice: <= $3.50Beta: HighRiskRevenue 5yr Cagr: >= 20Annual Eps Yoy Growth: >= 20.0%
Ticker
Name
Market Cap$
top bottom
CLVT logo
CLVT
Clarivate PLC
1.86B
BITF logo
BITF
Bitfarms Ltd
1.61B
BLND logo
BLND
Blend Labs Inc
732.49M
SNDL logo
SNDL
SNDL Inc
406.85M
LCTX logo
LCTX
Lineage Cell Therapeutics Inc
382.34M
SLQT logo
SLQT
SelectQuote Inc
283.31M

Whales Holding SLQT

A
Abrams Bison Investments, L.L.C.
Holding
SLQT
+18.14%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is SelectQuote Inc (SLQT) stock price today?

The current price of SLQT is 1.16 USD — it has decreased -2.52

What is SelectQuote Inc (SLQT)'s business?

SelectQuote, Inc. provides a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. The Company has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote Healthcare Services comprises SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with healthcare services that fit each member's healthcare needs. SelectQuote’s Auto & Home division primarily sells non-commercial auto and home, property and casualty insurance products. SelectQuote’s Life division sells term life, final expenses, and other ancillary products. SelectRx is a Patient-Centered Pharmacy Home (PCPH) accredited pharmacy.

What is the price predicton of SLQT Stock?

Wall Street analysts forecast SLQT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLQT is6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is SelectQuote Inc (SLQT)'s revenue for the last quarter?

SelectQuote Inc revenue for the last quarter amounts to 430.93M USD, increased 5.58

What is SelectQuote Inc (SLQT)'s earnings per share (EPS) for the last quarter?

SelectQuote Inc. EPS for the last quarter amounts to 0.11 USD, increased 266.67

How many employees does SelectQuote Inc (SLQT). have?

SelectQuote Inc (SLQT) has 1181 emplpoyees as of May 17 2026.

What is SelectQuote Inc (SLQT) market cap?

Today SLQT has the market capitalization of 204.56M USD.